DelveInsight’s, “Advanced Recurrent Ovarian Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the Advanced Recurrent Ovarian Cancer pipeline drug profiles, including Advanced Recurrent Ovarian Cancer clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Advanced Recurrent Ovarian Cancer Emerging drugs, the Advanced Recurrent Ovarian Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Advanced Recurrent Ovarian Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Advanced Recurrent Ovarian Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Advanced Recurrent Ovarian Cancer clinical trials studies, Advanced Recurrent Ovarian Cancer NDA approvals (if any), and product development activities comprising the technology, Advanced Recurrent Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

 

• DelveInsight’s Advanced Recurrent Ovarian Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.

 

• The leading Advanced Recurrent Ovarian Cancer Companies includes IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH, and others.

 

• Promising Advanced Recurrent Ovarian Cancer Pipeline Therapies includes Pembrolizumab, MEDI3617, Bevacizumab, Paclitaxel, Carboplatin, MM-121, DOXIL, Dexamethasone, BAY2287411, and others.

 

 

• The Advanced Recurrent Ovarian Cancer companies and academics are working to assess challenges and seek opportunities that could influence Advanced Recurrent Ovarian Cancer R&D. The Advanced Recurrent Ovarian Cancer pipeline therapies under development are focused on novel approaches to treat/improve Advanced Recurrent Ovarian Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Advanced Recurrent Ovarian Cancer Pipeline landscape @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report

 

Advanced Recurrent Ovarian Cancer Overview

Ovarian cancer refers to cancer that arises in the almond-shaped reproductive organs in women in which eggs, or ova, are produced (ovaries), in either of the two tubes through which eggs travel from the ovaries to the uterus (fallopian tubes), or in the membrane that lines the pelvis and the abdominal cavity and covers all of the abdominal organs (peritoneum). There are usually no symptoms (asymptomatic) during the early stages. As a result, ovarian cancer is usually not diagnosed until an advanced stage.

 

Recent Developmental Activities in the Advanced Recurrent Ovarian Cancer Treatment Landscape

 

• In April 1, 2023. FoundationOne CDx, a tissue-based comprehensive genomic profiling (CGP) test, and FoundationOne Liquid CDx, a CGP liquid biopsy test, are used to identify patients who may benefit from treatment with specific FDA-approved targeted therapies.

 

• Pembrolizumab is currently approved in two indications for endometrial cancer in the United States. In March 2022, the FDA approved pembrolizumab for use as a single agent in the treatment of patients with advanced endometrial carcinoma that is microsatellite instability–high (MSI-H) or dMMR, and who experienced disease progression following previous systemic therapy in any setting and are not candidates for curative surgery or radiation.

 

• Additionally, in July 2021, the FDA granted regular approval to pembrolizumab plus lenvatinib (Lenvima)for the treatment of patients with advanced endometrial carcinoma that is not MSI-H) or dMMR, who have disease progression after previous systemic therapy in any setting, and who are not candidates for curative surgery or radiation.

  

For further information, refer to the detailed Advanced Recurrent Ovarian Cancer Drugs Launch, Advanced Recurrent Ovarian Cancer Developmental Activities, and Advanced Recurrent Ovarian Cancer News, click here for Advanced Recurrent Ovarian Cancer Ongoing Clinical Trial Analysis

 

Advanced Recurrent Ovarian Cancer Emerging Drugs Profile

 

• Maveropepimut S: IMV

Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo. The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. It is believed Maveropepimut-S’ ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies. Maveropepimut-S has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post-treatment which is correlated with prolonged duration of clinical benefits up to more than two years. Maveropepimut-S showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, Maveropepimut-S provides lesser burden on patients’ quality of life.

 

• ELU 001: Elucida Oncology

ELU001 is a novel, first-in-class, new molecular entity described as a C’Dot Drug Conjugate (CDC). ELU001 consists of ~12 folic acid targeting moieties and ~22 exatecan topoisomerase-1 inhibitor payloads on Cathepsin-B cleavable linkers covalently bound to the surface of each silicon core/polyethylene glycol C’Dot nanoparticle. CDCs are small in size, have a greater ability to penetrate into and through tumors as compared to ADCs, and are rapidly eliminated by the kidneys. The rapid systemic elimination is expected to lead to less toxicity than is observed with targeting platforms like ADCs that have a longer half-life in circulation. ELU001’s high avidity is believed to promote internalization into FRα overexpressing cancer cells, selectively delivering its payload. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

 

• A166: Klus Pharma

A166 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-HER2 antibody conjugated to highly potent auristatin-based payload, via site-specific conjugation and cleavable Val-Cit linker. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Advanced Recurrent Ovarian Cancer.

 

Advanced Recurrent Ovarian Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Advanced Recurrent Ovarian Cancer. The companies which have their Advanced Recurrent Ovarian Cancer drug candidates in the most advanced stage, i.e. phase II include, IMV.

 

Find out more about the Advanced Recurrent Ovarian Cancer Pipeline Segmentation, Therapeutics Assessment, and Advanced Recurrent Ovarian Cancer Emerging Drugs @ Advanced Recurrent Ovarian Cancer Treatment Landscape

 

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

 

• Coverage- Global

 

• Advanced Recurrent Ovarian Cancer Companies- IMV, Elucida Oncology, Klus Pharma, Chia Tai Tianqing Pharmaceutical Group, Sumitomo Pharma Oncology, Precigen, Inc, Glycotope GmbH, and others.

 

• Advanced Recurrent Ovarian Cancer Pipeline Therapies- Pembrolizumab, MEDI3617, Bevacizumab, Paclitaxel, Carboplatin, MM-121, DOXIL, Dexamethasone, BAY2287411, and others.

 

• Advanced Recurrent Ovarian Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Advanced Recurrent Ovarian Cancer Pipeline Companies and Therapies, click here @ Advanced Recurrent Ovarian Cancer Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Recurrent Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Advanced Recurrent Ovarian Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Maveropepimut S: IMV
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Advanced Recurrent Ovarian Cancer Key Companies
21. Advanced Recurrent Ovarian Cancer Key Products
22. Advanced Recurrent Ovarian Cancer- Unmet Needs
23. Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
24. Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
25. Advanced Recurrent Ovarian Cancer Analyst Views
26. Advanced Recurrent Ovarian Cancer Key Companies
27. Appendix

 

Got Queries? Find out the related information on Advanced Recurrent Ovarian Cancer Mergers and acquisitions, Advanced Recurrent Ovarian Cancer Licensing Activities @ Advanced Recurrent Ovarian Cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/